Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant Advanced NSCLC
Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC.
Related Articles
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
ICR joins £10million UK-wide AI data project to help identify cancer risk
ICR joins £10million AI project to help identify individual cancer risk
Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis
Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.
Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS
Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.
Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape
A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud…
Considerations for Treatment Sequencing in LR-MDS
Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes (LR-MDS) include limited access to newer therapies, patient-specific factors,…
FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
Dr Dronca discusses the FDA approval of subcutaneous nivolumab and hyaluronidase for advanced or metastatic solid tumors.
The Spirit of Community Brings Together Many in Support of Cancer Research and Care
Fox Chase Cancer Center’s mission of Discovery and Delivery extends well beyond its faculty and staff to include many throughout the community.
Research and Education Fund Tiered Giving Program – Society of Surgical Oncology
Research and Education Fund Tiered Giving The Research and Education Fund (REF) Tiered Giving Program recognizes donors whose contributions since 2014 have collectively advanced cancer…
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer
Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.